MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

MDT

88.97

-0.32%↓

VEEV

280.11

-0.04%↓

A

114.58

+1.24%↑

WBA

11.51

0%↓

HQY

99.14

+2.32%↑

Search

Revvity Inc

Closed

SectorHealthcare

94.86 -1.11

Overview

Share price change

24h

Current

Min

94.01

Max

96.19

Key metrics

By Trading Economics

Income

-53M

42M

Sales

-65M

665M

P/E

Sector Avg

40.69

39.857

EPS

1.01

Dividend yield

0.29

Profit margin

6.268

Employees

11,000

EBITDA

-50M

173M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+22.08% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.29%

2.42%

Next Earnings

28 Jul 2025

Next Dividend date

8 Aug 2025

Next Ex Dividend date

18 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-2.4B

12B

Previous open

95.97

Previous close

94.86

News Sentiment

By Acuity

27%

73%

68 / 376 Healthcare

Revvity Inc Chart

Past performance is not a reliable indicator of future results.

Related News

16 Jul 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 Jul 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 Jul 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 Jul 2025, 22:38 UTC

Acquisitions, Mergers, Takeovers

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 Jul 2025, 23:44 UTC

Market Talk

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 Jul 2025, 23:42 UTC

Market Talk

Nikkei May Fall as Yen Strengthens -- Market Talk

16 Jul 2025, 23:24 UTC

Market Talk

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 Jul 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 Jul 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Santos Cuts Top End of 2025 Production Guidance

16 Jul 2025, 23:17 UTC

Acquisitions, Mergers, Takeovers

Santos: Production Recovery Underway in Cooper Basin

16 Jul 2025, 23:17 UTC

Acquisitions, Mergers, Takeovers

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 Jul 2025, 23:17 UTC

Acquisitions, Mergers, Takeovers

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 Jul 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 Jul 2025, 23:16 UTC

Acquisitions, Mergers, Takeovers

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 Jul 2025, 23:13 UTC

Acquisitions, Mergers, Takeovers

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 Jul 2025, 23:13 UTC

Acquisitions, Mergers, Takeovers

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 Jul 2025, 23:12 UTC

Acquisitions, Mergers, Takeovers

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 Jul 2025, 23:12 UTC

Acquisitions, Mergers, Takeovers

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Free Cash Flow From Operations US$620 Million

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 Jul 2025, 23:11 UTC

Acquisitions, Mergers, Takeovers

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 Jul 2025, 22:43 UTC

Market Talk

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 Jul 2025, 22:35 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

16 Jul 2025, 22:35 UTC

Market Talk
Earnings

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 Jul 2025, 22:33 UTC

Market Talk
Earnings

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 Jul 2025, 22:28 UTC

Market Talk
Earnings

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 Jul 2025, 22:22 UTC

Market Talk
Earnings

Market Talk Roundup: Latest on U.S. Politics

16 Jul 2025, 22:22 UTC

Market Talk
Earnings

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Peer Comparison

Price change

Revvity Inc Forecast

Price Target

By TipRanks

22.08% upside

12 Months Forecast

Average 117.07 USD  22.08%

High 135 USD

Low 100 USD

Based on 14 Wall Street analysts offering 12 month price targets forRevvity Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

9

Buy

5

Hold

0

Sell

Sentiment

By Acuity

68 / 376 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.